All In Biotech

Drug Trial Radar · NCT05795517

Study of HSK31679 in Subjects With Hypercholesterolemia With Nonalcoholic Fatty Liver Disease(NAFLD)

A Phase 2 ,Multicentre, Randomised, Double Blind Double Simulation, Placebo and Positive Controlled Study to Evaluate the Efficacy and Safety of HSK31679 in Patients With Hypercholesterolemia With Non-alcoholic Fatty Liver Disease

Last checked: Nov 20, 2026Latest source record: Apr 9, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 210 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

210

Actual

Start

Apr 26, 2023

Primary completion

Feb 20, 2024

Study completion Mar 1, 2024

Sponsor

Sponsor type
Industry
First posted
Apr 3, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the efficacy and safety of HSK31679 tablets compared with placebo in reducing low-density lipoprotein cholesterol (LDL-C) and MRI-PDFF after 12 weeks of treatment in patients with hypercholesterolemia and non-alcoholic fatty liver disease (NAFLD).

Conditions

  • Hypercholesterolemia

Interventions

  • HSK31679 low doseDrug

    HSK31679 low dose and placebo of HSK31679 ,QD,oral,Day1 to week 12

  • HSK31679 medium doseDrug

    HSK31679 medium dose and placebo of HSK31679 ,QD,oral,Day1 to week 12

  • HSK31679 high doseDrug

    HSK31679 high dose and placebo of HSK31679 ,QD,oral,Day1 to week 12

  • PlaceboDrug

    placebo ,QD,oral,Day1 to week 12

  • Ezetimibe 10mgDrug

    Ezetimibe 10mg+placebo of HSK31679 ,QD,oral,Day1 to week 12

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage change in LDL-C from baseline at 12 week;Time frame: Baseline and Week 12
  2. Percentage change in MRI-PDFF from baseline at 12 week;Time frame: Baseline and Week 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Tsinghua Changgung Hospital, Tsinghua University

    Beijing, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.